Table 1. General, Clinicopathological and PET/CT Semi-Quantitatively Parameters and EGFR/ALK Mutation Status in 419 IA-IIIA Patients.
| Characteristics | Total | AIS | MIA | Lepidic Predominant | Acinar Predominant | Papillary Predominant | Micropapillary Predominant | Solid Predominant | Variant | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of patients | 419 | 22 (5.3) | 37 (8.8) | 60 (14.3) | 202 (48.2) | 22 (5.3) | 8 (1.9) | 30 (7.2) | 38 (9.1) | |
| Age*, year | 59 (23–84) | 57 (51–66) | 55 (33–69) | 61 (23–78) | 60 (32–84) | 61 (51–72) | 50 (38–71) | 61 (48–74) | 63 (44–80) | |
| Sex | ||||||||||
| Male | 150 (35.8) | 0 | 6 | 22 | 72 | 8 | 2 | 22 | 18 | |
| Female | 269 (64.2) | 22 | 31 | 38 | 130 | 14 | 6 | 8 | 20 | |
| TNM stage | ||||||||||
| IA | 303 (72.3) | 22 | 37 | 46 | 154 | 6 | 4 | 14 | 20 | |
| IB + IIA | 44 (10.5) | 0 | 0 | 6 | 20 | 8 | 2 | 2 | 6 | |
| IIB + IIIA | 72 (17.2) | 0 | 0 | 8 | 28 | 8 | 2 | 14 | 12 | |
| Lung lesion shape | ||||||||||
| Pure GGN | 37 (8.8) | 16 | 9 | 8 | 4 | 0 | 0 | 0 | 0 | |
| Subsolid nodule | 54 (12.9) | 3 | 11 | 18 | 18 | 2 | 0 | 0 | 2 | |
| Solid nodule | 238 (56.8) | 3 | 17 | 28 | 144 | 4 | 4 | 20 | 18 | |
| Mass | 90 (21.5) | - | - | 6 | 36 | 16 | 4 | 10 | 18 | |
| Tumor size*, cm | 2.0 (0.4–7.5) | 0.9 (0.4–1.6) | 1.1 (0.6–1.4) | 1.8 (0.9–5.1) | 2.1 (0.9–4.6) | 4.0 (1.1–6.6) | 3.2 (2.0–3.6) | 2.7 (1.1–5.7) | 2.5 (1.3–7.5) | |
| PET/CT | ||||||||||
| SUVmax* | 4.2 (0.6–20.5) | 0.7 (0.6–2.3) | 1.4 (0.7–5.5) | 2.4 (0.7–14.5) | 6.3 (1.4–20.2) | 4.3 (1.95–13.1) | 14.2 (4.7–19.2) | 12.2 (3.3–20.5) | 5.7 (2.2–20.3) | |
| BSV*, cm3 | 6.5 (0.6–166) | 1.0 (0.7–7.5) | 3.2 (0.6–14.1) | 8.8 (2.0–26.7) | 6.2 (1.1–39.3) | 14.6 (4.8–71.1) | 10.6 (2.8–14.7) | 13.4 (1.0–33.3) | 17.5 (3.4–166.0) | |
| BSL (x 103)*, g | 14.6 (1.2–188.6) | 1.4 (1.3–7.8) | 6.2 (1.2–15.4) | 9.0 (2.9–88.3) | 16.8 (1.8–172.3) | 35.2 (7.2–189.0) | 36.0 (28.8–152.2) | 47.3 (5.1–286.4) | 25.0 (5.5–188.6) | |
| Ki67, % | ||||||||||
| Absolute value* | 18.2 (1–88) | 4.8 (1–10) | 7.8 (5–20) | 10.0 (2–30) | 19.4 (1–88) | 9.4 (2–30) | 16.3 (2–30) | 25.1 (1–60) | 20.1 (2–80) | |
| Ki67 > 20 | 113 (27.0) | 0 | 3 | 4 | 38 | 2 | 4 | 16 | 8 | |
| Ki67 ≤ 20 | 306 (73.0) | 11 | 6 | 42 | 124 | 18 | 4 | 14 | 22 | |
| EGFR | ||||||||||
| Wild-type | 41/194 (21.1) | 3/8 (37.5) | 2/20 (10) | 0/16 (0) | 18/104 (17.3) | 0/12 (0) | 2/8 (25) | 4/8 (50) | 12/18 (66.7) | |
| Mutant | 153/194 (78.9) | 5/8 (62.5) | 18/20 (90) | 16/16 (100) | 86/104 (82.7) | 12/12 (100) | 6/8 (75) | 4/8 (50) | 6/18 (33.3) | |
| ALK | ||||||||||
| Negative | 277/287 (96.5) | 20/20 (100) | 27/27 (100) | 26/26 (100) | 144/146 (98.6) | 14/14 (100) | 6/6 (100) | 18/18 (100) | 22/30 (73.3) | |
| Positive | 10/287 (3.5) | 0/20 (0) | 0/27 (0) | 0/26 (0) | 2/146 (1.4) | 0/14 (0) | 0/6 (0) | 0/18 (0) | 8/30 (26.7) | |
*Data are medians with ranges in parentheses. Otherwise, data are the number of patients with percentages in parentheses. AIS = adenocarcinoma in situ, ALK = anaplastic lymphoma kinase, BSL = background subtracted lesion activity, BSV = background subtracted volume, EGFR = epidermal growth factor receptor, GGN = ground-glass nodule, MIA = minimally invasive adenocarcinoma, SUVmax = maximum standardized uptake value